Cardio Diagnostics enters $17M at-the-market equity offering with Craig-Hallum

Cardio Diagnostics Holdings, Inc.

Up to $17M in common stock may be sold via Craig-Hallum as sales agent under an ATM offering.
Craig-Hallum will receive 2.5% commission on gross proceeds; legal fee reimbursement up to $55,000.
Proceeds to be used for general corporate purposes, including working capital and capex.
Registration statement on Form S-3 declared effective by SEC on February 1, 2024.
Sales may be made on Nasdaq Capital Market through ordinary brokers' transactions or negotiated deals.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

Cardio Diagnostics Holdings, Inc. entered into Sales Agreement with Craig-Hallum Capital Group LLC valued at up to an aggregate of $17 million (effective 2024-01-26).

Action: entry
Agreement: atm program
Counterparty: Craig-Hallum Capital Group LLC
Value: up to an aggregate of $17 million
Effective: 2024-01-26

Exact text from the filing

On January 26, 2024, Cardio Diagnostics Holdings, Inc. (the “Company”) entered into an At-the-Market Issuance Sales Agreement (the “Sales Agreement”) with Craig-Hallum Capital Group LLC (“Craig-Hallum”). Pursuant to the Sales Agreement, the Company may sell, at its option, up to an aggregate of $17 million in shares of its common stock through Craig-Hallum, as sales agent.

View on SEC.gov

Browse all material agreements →

Cardio Diagnostics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001079973-24-000169

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.